Lutetium-177 (BioDeep_00000839318)
代谢物信息卡片
Lutetium-177
化学式: Lu (174.940785)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: [Lu]
InChI: InChI=1S/Lu/i1+2
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Thomas Ertveldt, Lien De Beck, Kirsten De Ridder, Hanne Locy, Wout de Mey, Cleo Goyvaerts, Quentin Lecocq, Hannelore Ceuppens, Yannick De Vlaeminck, Robin Maximilian Awad, Marleen Keyaerts, Nick Devoogdt, Matthias D'Huyvetter, Karine Breckpot, Ahmet Krasniqi. Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model.
Molecular cancer therapeutics.
2022 Jul; 21(7):1136-1148. doi:
10.1158/1535-7163.mct-21-0791. [PMID: 35499391] - Sreeja Raj Menon, Arpit Mitra, Avik Chakraborty, Megha Tawate, Sudeep Sahu, Sutapa Rakshit, Sujay Gaikwad, Geetanjali Dhotre, Archana Damle, Sharmila Banerjee. Clinical Dose Preparation of [177Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [177Lu]LuCl3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression.
Cancer biotherapy & radiopharmaceuticals.
2022 Jun; 37(5):384-402. doi:
10.1089/cbr.2021.0230. [PMID: 35575711] - Fadi Khreish, Zaidoon Ghazal, Robert J Marlowe, Florian Rosar, Amir Sabet, Stephan Maus, Johannes Linxweiler, Mark Bartholomä, Samer Ezziddin. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
European journal of nuclear medicine and molecular imaging.
2022 02; 49(3):1075-1085. doi:
10.1007/s00259-021-05525-7. [PMID: 34494131] - Joanna Matalińska, Katarzyna Kosińska, Paweł K Halik, Przemysław Koźmiński, Piotr F J Lipiński, Ewa Gniazdowska, Aleksandra Misicka. Novel NK1R-Targeted 68Ga-/177Lu-Radioconjugates with Potential Application against Glioblastoma Multiforme: Preliminary Exploration of Structure-Activity Relationships.
International journal of molecular sciences.
2022 Jan; 23(3):. doi:
10.3390/ijms23031214. [PMID: 35163139] - Liam Widjaja, Thorsten Derlin, Tobias L Ross, Frank M Bengel, Rudolf A Werner. Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy.
The Prostate.
2022 01; 82(1):86-96. doi:
10.1002/pros.24250. [PMID: 34633090] - Amit Nautiyal, Ashish K Jha, Sneha Mithun, Bhakti Shetye, Mythili Kameswaran, Sneha Shah, Venkatesh Rangarajan, Sudeep Gupta. Analysis of absorbed dose in radioimmunotherapy with 177Lu-trastuzumab using two different imaging scenarios: a pilot study.
Nuclear medicine communications.
2021 Dec; 42(12):1382-1395. doi:
10.1097/mnm.0000000000001472. [PMID: 34406146] - Byoung Se Lee, Min Hwan Kim, So Young Chu, Woon Jung Jung, Hyeon Jin Jeong, Kyongkyu Lee, Hyeon Seok Kim, Mi Hyun Kim, Hee Seup Kil, Sang Jin Han, Yong Jin Lee, Kyo Chul Lee, Sang Moo Lim, Dae Yoon Chi. Improving Theranostic Gallium-68/Lutetium-177-Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer.
Molecular cancer therapeutics.
2021 12; 20(12):2410-2419. doi:
10.1158/1535-7163.mct-21-0251. [PMID: 34725194] - Elodie Duray, Margaux Lejeune, Frederic Baron, Yves Beguin, Nick Devoogdt, Ahmet Krasniqi, Yoline Lauwers, Yong Juan Zhao, Matthias D'Huyvetter, Mireille Dumoulin, Jo Caers. A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma.
Journal of hematology & oncology.
2021 11; 14(1):183. doi:
10.1186/s13045-021-01171-6. [PMID: 34727950] - Ugo De Giorgi, Maddalena Sansovini, Stefano Severi, Silvia Nicolini, Manuela Monti, Giorgia Gurioli, Flavia Foca, Chiara Casadei, Vincenza Conteduca, Monica Celli, Valentina Di Iorio, Daniele Calistri, Federica Matteucci, Finn Edler von Eyben, Gerhardt Attard, Giovanni Paganelli. Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial.
British journal of cancer.
2021 10; 125(9):1226-1232. doi:
10.1038/s41416-021-01508-5. [PMID: 34333554] - Avik Chakraborty, Arpit Mitra, Megha Tawate, Sudip Sahoo, Sangita Lad, Sutapa Rakshit, Sujay Gaikwad, Sandip Basu, Hemant Shimpi, Sharmila Banerjee. Therapeutic Multidose Preparation of a Ready-to-Use 177Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy.
Cancer biotherapy & radiopharmaceuticals.
2021 Oct; 36(8):682-692. doi:
10.1089/cbr.2020.4261. [PMID: 34402687] - Cigdem Soydal, Mine Araz, Yuksel Urun, Demet Nak, Elgin Ozkan, Nuriye O Kucuk. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
2021 Sep; 65(3):282-286. doi:
10.23736/s1824-4785.19.03165-0. [PMID: 31602963] - Luisa M Deberle, Martina Benešová, Anna E Becker, Magdalena Ratz, Patrycja Guzik, Roger Schibli, Cristina Müller. Novel Synthetic Strategies Enable the Efficient Development of Folate Conjugates for Cancer Radiotheranostics.
Bioconjugate chemistry.
2021 08; 32(8):1617-1628. doi:
10.1021/acs.bioconjchem.1c00198. [PMID: 34251183] - Hyun-Soon Chong, Yunwei Chen, Chi Soo Kang, Inseok Sin, Shuyuan Zhang, Haixing Wang. Pyridine-containing octadentate ligand NE3TA-PY for formation of neutral complex with 177Lu(III) and 90Y(III) for radiopharmaceutical applications: Synthesis, DFT calculation, radiolabeling, and in vitro complex stability.
Journal of inorganic biochemistry.
2021 08; 221(?):111436. doi:
10.1016/j.jinorgbio.2021.111436. [PMID: 33971521] - Mehmet Onur Demirkol, Ahu Özkan, Burcu Uçar, Hans-Jürgen Wester, Burhan Ferhanoğlu. Extramedullary Relapsed Multiple Myeloma Treatment With 177Lu-Labeled CXCR4 Endoradiotherapy and Dosimetric Results.
Clinical nuclear medicine.
2021 Aug; 46(8):656-658. doi:
10.1097/rlu.0000000000003705. [PMID: 34034308] - Mohammad S Sadaghiani, Sara Sheikhbahaei, Rudolf A Werner, Kenneth J Pienta, Martin G Pomper, Lilja B Solnes, Michael A Gorin, Nae-Yuh Wang, Steven P Rowe. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
European urology.
2021 07; 80(1):82-94. doi:
10.1016/j.eururo.2021.03.004. [PMID: 33840558] - Danielle Meyrick, Marat Gallyamov, Shanthi Sabarimurugan, Nadia Falzone, Nat Lenzo. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Targeted oncology.
2021 05; 16(3):369-380. doi:
10.1007/s11523-021-00801-w. [PMID: 33687624] - Eline A M Ruigrok, Nicole van Vliet, Simone U Dalm, Erik de Blois, Dik C van Gent, Joost Haeck, Corrina de Ridder, Debra Stuurman, Mark W Konijnenberg, Wytske M van Weerden, Marion de Jong, Julie Nonnekens. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
European journal of nuclear medicine and molecular imaging.
2021 05; 48(5):1339-1350. doi:
10.1007/s00259-020-05057-6. [PMID: 33094433] - Sebastian Martin, Roswitha Tönnesmann, Ina Hierlmeier, Stephan Maus, Florian Rosar, Juri Ruf, Jason P Holland, Samer Ezziddin, Mark D Bartholomä. Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [177Lu]Lu-PSMA-617.
Journal of medicinal chemistry.
2021 04; 64(8):4960-4971. doi:
10.1021/acs.jmedchem.1c00045. [PMID: 33826320] - Tobias Rydén, Martijn Van Essen, Ida Marin, Johanna Svensson, Peter Bernhardt. Deep-Learning Generation of Synthetic Intermediate Projections Improves 177Lu SPECT Images Reconstructed with Sparsely Acquired Projections.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2021 04; 62(4):528-535. doi:
10.2967/jnumed.120.245548. [PMID: 32859710] - Hsiou-Ting Kuo, Kuo-Shyan Lin, Zhengxing Zhang, Carlos F Uribe, Helen Merkens, Chengcheng Zhang, François Bénard. 177Lu-Labeled Albumin-Binder-Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2021 04; 62(4):521-527. doi:
10.2967/jnumed.120.250738. [PMID: 32859704] - Amanda Kristiansson, Anders Örbom, Jonas Ahlstedt, Helena Karlsson, Wahed Zedan, Magnus Gram, Bo Åkerström, Sven-Erik Strand, Mohamed Altai, Joanna Strand, Oskar Vilhelmsson Timmermand. 177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging.
Biomolecules.
2021 02; 11(2):. doi:
10.3390/biom11020263. [PMID: 33579037] - Mohini Guleria, Jeyachitra Amirdhanayagam, Haladhar D Sarma, Ramya Priya Rallapeta, V S Krishnamohan, Ajit Nimmagadda, Parthasarathy Ravi, Sailaja Patri, Tekchand Kalawat, Tapas Das. Preparation of 177Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House.
BioMed research international.
2021; 2021(?):1555712. doi:
10.1155/2021/1555712. [PMID: 34845436] - Wen-Ting K Tsai, Kirstin A Zettlitz, Magnus Dahlbom, Robert E Reiter, Anna M Wu. Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer.
Molecular imaging and biology.
2020 10; 22(5):1380-1391. doi:
10.1007/s11307-020-01518-4. [PMID: 32661830] - Rosalba Mansi, Guillaume Pierre Nicolas, Luigi Del Pozzo, Karim Alexandre Abid, Eric Grouzmann, Melpomeni Fani. Evaluation of a New 177Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5.
Molecules (Basel, Switzerland).
2020 Sep; 25(18):. doi:
10.3390/molecules25184155. [PMID: 32932783] - Ajay-Mohan Mohan, Mathias Lukas, Jakob Albrecht, Viktoria Dorau-Rutke, Eva J Koziolek, Kai Huang, Sonal Prasad, Winfried Brenner, Nicola Beindorff. Relationship of Renal Function in Mice to Strain, Sex and 177Lutetium-Somatostatin Receptor Ligand Treatment.
Nuklearmedizin. Nuclear medicine.
2020 Sep; 59(5):381-386. doi:
10.1055/a-1103-1661. [PMID: 32074660] - John A Kennedy, Rachel Lugassi, Ronit Gill, Zohar Keidar. Digital Solid-State SPECT/CT Quantitation of Absolute 177Lu Radiotracer Concentration: In Vivo and In Vitro Validation.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2020 09; 61(9):1381-1387. doi:
10.2967/jnumed.119.239277. [PMID: 32111686] - Cati Raluca Stolniceanu, Ionut Nistor, Stefana Catalina Bilha, Volovat Constantin, Volovat Simona, Milovan Matovic, Cipriana Stefanescu, Adrian Covic. Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review.
Nuclear medicine communications.
2020 Jul; 41(7):601-617. doi:
10.1097/mnm.0000000000001198. [PMID: 32404645] - Luisa M Deberle, Viviane J Tschan, Francesca Borgna, Fan Sozzi-Guo, Peter Bernhardt, Roger Schibli, Cristina Müller. Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile.
Molecules (Basel, Switzerland).
2020 May; 25(11):. doi:
10.3390/molecules25112542. [PMID: 32486054] - Maria Luisa Belli, Emilio Mezzenga, Valentina Di Iorio, Monica Celli, Paola Caroli, Elisabeth Canali, Federica Matteucci, Elisa Tardelli, Ilaria Grassi, Maddalena Sansovini, Silvia Nicolini, Stefano Severi, Marta Cremonesi, Mahila Ferrari, Giovanni Paganelli, Anna Sarnelli. A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods.
Journal of visualized experiments : JoVE.
2020 04; ?(158):. doi:
10.3791/60477. [PMID: 32391816] - Christof Rottenburger, Guillaume P Nicolas, Lisa McDougall, Felix Kaul, Michal Cachovan, A Hans Vija, Roger Schibli, Susanne Geistlich, Anne Schumann, Tilman Rau, Katharina Glatz, Martin Behe, Emanuel R Christ, Damian Wild. Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2020 04; 61(4):520-526. doi:
10.2967/jnumed.119.233031. [PMID: 31519804] - Luisa M Deberle, Martina Benešová, Christoph A Umbricht, Francesca Borgna, Manuel Büchler, Konstantin Zhernosekov, Roger Schibli, Cristina Müller. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Theranostics.
2020; 10(4):1678-1693. doi:
10.7150/thno.40482. [PMID: 32042329] - Bhavesh D Kevadiya, Brendan Ottemann, Insiya Z Mukadam, Laura Castellanos, Kristen Sikora, James R Hilaire, Jatin Machhi, Jonathan Herskovitz, Dhruvkumar Soni, Mahmudul Hasan, Wenting Zhang, Sarella Anandakumar, Jered Garrison, JoEllyn McMillan, Benson Edagwa, R Lee Mosley, Richard W Vachet, Howard E Gendelman. Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues.
Theranostics.
2020; 10(2):630-656. doi:
10.7150/thno.39847. [PMID: 31903142] - Sonam Suman, Rahul V Parghane, Amit Joshi, Kumar Prabhash, Ganesh Bakshi, Sanjay Talole, Sharmila Banerjee, Sandip Basu. Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort.
The British journal of radiology.
2019 Dec; 92(1104):20190380. doi:
10.1259/bjr.20190380. [PMID: 31600089] - Diane Reidy-Lagunes, Neeta Pandit-Taskar, Joseph A O'Donoghue, Simone Krebs, Kevin D Staton, Serge K Lyashchenko, Jason S Lewis, Nitya Raj, Mithat Gönen, Christian Lohrmann, Lisa Bodei, Wolfgang A Weber. Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2019 12; 25(23):6939-6947. doi:
10.1158/1078-0432.ccr-19-1026. [PMID: 31439583] - Mohini Guleria, Tapas Das, Jeyachitra Amirdhanayagam, Haladhar D Sarma, Ashutosh Dash. Preparation of [177Lu]Lu-DOTA-Ahx-Lys40-Exendin-4 for radiotherapy of insulinoma: a detailed insight into the radiochemical intricacies.
Nuclear medicine and biology.
2019 Nov; 78-79(?):31-40. doi:
10.1016/j.nucmedbio.2019.11.003. [PMID: 31731177] - Rhiannon McBean, Brooke O'Kane, Rex Parsons, David Wong. Lu177-PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution.
Journal of medical imaging and radiation oncology.
2019 Aug; 63(4):538-545. doi:
10.1111/1754-9485.12891. [PMID: 31021525] - Neha Choudhary, Alexander Dimmling, Xiaozhu Wang, Lily Southcott, Valery Radchenko, Brian O Patrick, Peter Comba, Chris Orvig. Octadentate Oxine-Armed Bispidine Ligand for Radiopharmaceutical Chemistry.
Inorganic chemistry.
2019 Jul; 58(13):8685-8693. doi:
10.1021/acs.inorgchem.9b01016. [PMID: 31247868] - Th I Götz, C Schmidkonz, E W Lang, A Maier, T Kuwert, P Ritt. Factors affecting accuracy of S values and determination of time-integrated activity in clinical Lu-177 dosimetry.
Annals of nuclear medicine.
2019 Jul; 33(7):521-531. doi:
10.1007/s12149-019-01365-6. [PMID: 31119607] - Usha Pandey, Suresh Subramanian, Samina Shaikh, Naresh Gamre, Sanjukta Kumar, Ashutosh Dash. Synthesis and Preliminary Biological Evaluation of 177Lu-Labeled Polyhydroxamic Acid Microparticles Toward Therapy of Hepatocellular Carcinoma.
Cancer biotherapy & radiopharmaceuticals.
2019 Jun; 34(5):306-315. doi:
10.1089/cbr.2018.2747. [PMID: 31188652] - Hendrik Rathke, Paul Flechsig, Walter Mier, Marcus Bronzel, Eleni Mavriopoulou, Markus Hohenfellner, Frederik Lars Giesel, Uwe Haberkorn, Clemens Kratochwil. Dosimetry Estimate and Initial Clinical Experience with 90Y-PSMA-617.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2019 Jun; 60(6):806-811. doi:
10.2967/jnumed.118.218917. [PMID: 30389816] - Rahul V Parghane, Sandip Basu. Bilateral Orbital Soft-Tissue Metastases from Renal Neuroendocrine Tumor: Successful Theranostic Application of 68Ga/177Lu-DOTATATE with Improvement of Vision.
Journal of nuclear medicine technology.
2019 Jun; 47(2):171-172. doi:
10.2967/jnmt.118.217455. [PMID: 30139884] - Jie Zhang, Zi Wang, Huipan Liu, Liang Cai, Yue Feng, Ling Zhou, Hongyuan Wei, Ying Xie, Yue Chen. In vivo and in vitro evaluation of 177Lu-labeled DOTA-2-deoxy-D-glucose in mice. A novel radiopharmaceutical agent for cells imaging and therapy.
Hellenic journal of nuclear medicine.
2019 May; 22(2):103-110. doi:
10.1967/s002449911002. [PMID: 31273351] - John Violet, Price Jackson, Justin Ferdinandus, Shahneen Sandhu, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Sue Ping Thang, Peter Eu, Mark Scalzo, Declan Murphy, Scott Williams, Rodney J Hicks, Michael S Hofman. Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2019 04; 60(4):517-523. doi:
10.2967/jnumed.118.219352. [PMID: 30291192] - Anna Sarnelli, Maria Luisa Belli, Valentina Di Iorio, Emilio Mezzenga, Monica Celli, Stefano Severi, Elisa Tardelli, Silvia Nicolini, Devil Oboldi, Licia Uccelli, Corrado Cittanti, Manuela Monti, Mahila Ferrari, Giovanni Paganelli. Dosimetry of 177Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol.
Molecules (Basel, Switzerland).
2019 Feb; 24(3):. doi:
10.3390/molecules24030621. [PMID: 30754620] - Seval Beykan, Melpomeni Fani, Svend Borup Jensen, Guillaume Nicolas, Damian Wild, Jens Kaufmann, Michael Lassmann. In Vivo Biokinetics of 177Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry.
Contrast media & molecular imaging.
2019; 2019(?):6438196. doi:
10.1155/2019/6438196. [PMID: 30733648] - Syed Faheem Askari Rizvi, Syed Ali Raza Naqvi, Samina Roohi, Tauqir A Sherazi, Rashid Rasheed. 177Lu-DOTA-coupled minigastrin peptides: promising theranostic agents in neuroendocrine cancers.
Molecular biology reports.
2018 Dec; 45(6):1759-1767. doi:
10.1007/s11033-018-4319-0. [PMID: 30143975] - Janine Schniering, Francesca Borgna, Klaudia Siwowska, Martina Benešová, Susan Cohrs, Roger Hasler, Nicholas P van der Meulen, Britta Maurer, Roger Schibli, Cristina Müller. In Vivo Labeling of Plasma Proteins for Imaging of Enhanced Vascular Permeability in the Lungs.
Molecular pharmaceutics.
2018 11; 15(11):4995-5004. doi:
10.1021/acs.molpharmaceut.8b00606. [PMID: 30265552] - Jingjing Zhang, Hao Wang, Orit Jacobson, Yuejuan Cheng, Gang Niu, Fang Li, Chunmei Bai, Zhaohui Zhu, Xiaoyuan Chen. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2018 11; 59(11):1699-1705. doi:
10.2967/jnumed.118.209841. [PMID: 29653971] - Cristina Müller, Patrycja Guzik, Klaudia Siwowska, Susan Cohrs, Raffaella M Schmid, Roger Schibli. Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates.
Molecules (Basel, Switzerland).
2018 06; 23(6):. doi:
10.3390/molecules23061465. [PMID: 29914162] - Christoph A Umbricht, Martina Benešová, Roger Schibli, Cristina Müller. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Molecular pharmaceutics.
2018 06; 15(6):2297-2306. doi:
10.1021/acs.molpharmaceut.8b00152. [PMID: 29684274] - Lucy F Matthews, Ivor W Jones. The effect of kidney volume estimation on dosimetry in lutetium-177 DOTATATE therapy.
Nuclear medicine communications.
2018 Jun; 39(6):527-532. doi:
10.1097/mnm.0000000000000821. [PMID: 29528911] - Nusrat J Begum, Anne Thieme, Nina Eberhardt, Robert Tauber, Calogero D'Alessandria, Ambros J Beer, Gerhard Glatting, Matthias Eiber, Peter Kletting. The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for 177Lu-Labeled PSMA Peptides.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2018 06; 59(6):929-933. doi:
10.2967/jnumed.117.203505. [PMID: 29419479] - Johannes Tran-Gia, Michael Lassmann. Optimizing Image Quantification for 177Lu SPECT/CT Based on a 3D Printed 2-Compartment Kidney Phantom.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2018 04; 59(4):616-624. doi:
10.2967/jnumed.117.200170. [PMID: 29097409] - Martina Benešová, Christoph A Umbricht, Roger Schibli, Cristina Müller. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Molecular pharmaceutics.
2018 03; 15(3):934-946. doi:
10.1021/acs.molpharmaceut.7b00877. [PMID: 29400475] - Sadaf Aghevlian, Yijie Lu, Mitchell A Winnik, David W Hedley, Raymond M Reilly. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer.
Molecular pharmaceutics.
2018 03; 15(3):1150-1159. doi:
10.1021/acs.molpharmaceut.7b01000. [PMID: 29314858] - Grzegorz Wójciuk, Marcin Kruszewski. [DTPA-(PABn)-Leu5]-des-acyl ghrelin(1-5) as a new carrier of radionuclides and potential precursor of radiopharmaceuticals.
Nuclear medicine communications.
2018 Feb; 39(2):140-146. doi:
10.1097/mnm.0000000000000790. [PMID: 29315139] - Clara Santos-Cuevas, Guillermina Ferro-Flores, Francisco O García-Pérez, Nallely Jiménez-Mancilla, Gerardo Ramírez-Nava, Blanca Ocampo-García, Myrna Luna-Gutiérrez, Erika Azorín-Vega, Jenny Davanzo, Irma Soldevilla-Gallardo. 177Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer.
Contrast media & molecular imaging.
2018; 2018(?):5247153. doi:
10.1155/2018/5247153. [PMID: 30534027] - Agnieszka Kolasińska-Ćwikła, Anna Łowczak, Katarzyna Maciejkiewicz Maciejkiewicz, Jarosław Bogdan Ćwikła. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Nuclear medicine review. Central & Eastern Europe.
2018; 21(2):. doi:
10.5603/nmr.2018.0019. [PMID: 29741203] - Tilman Läppchen, Raffaella Rossin, Tiemen R van Mourik, Guillaume Gruntz, Freek J M Hoeben, Ron M Versteegen, Henk M Janssen, Johan Lub, Marc S Robillard. DOTA-tetrazine probes with modified linkers for tumor pretargeting.
Nuclear medicine and biology.
2017 Dec; 55(?):19-26. doi:
10.1016/j.nucmedbio.2017.09.001. [PMID: 29028502] - Mohamed Altai, Kristina Westerlund, Justin Velletta, Bogdan Mitran, Hadis Honarvar, Amelie Eriksson Karlström. Evaluation of affibody molecule-based PNA-mediated radionuclide pretargeting: Development of an optimized conjugation protocol and 177Lu labeling.
Nuclear medicine and biology.
2017 Nov; 54(?):1-9. doi:
10.1016/j.nucmedbio.2017.07.003. [PMID: 28810153] - Muhammad Adeel Shahzad, Syed Ali Raza Naqvi, Rashid Rasheed, Muhammad Yameen, Fozia Anjum, Muhammad Tauqeer Ahmed, Zaib Hussain, Syed Jawad Hussain Gillani. Radiolabeling of benzylpenicillin with lutetium-177: Quality control and biodistribution study to develop theranostic infection imaging agent.
Pakistan journal of pharmaceutical sciences.
2017 Nov; 30(6(Supplementary)):2349-2354. doi:
. [PMID: 29188768] - Anna Yordanova, Anja Becker, Elisabeth Eppard, Stefan Kürpig, Christian Fisang, Georg Feldmann, Markus Essler, Hojjat Ahmadzadehfar. The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer.
European journal of nuclear medicine and molecular imaging.
2017 Aug; 44(9):1473-1479. doi:
10.1007/s00259-017-3681-9. [PMID: 28337529] - M Estorch. Treatment with 177Lu-DOTATATE: Past, present and future.
Revista espanola de medicina nuclear e imagen molecular.
2017 Mar; 36(2):69-71. doi:
10.1016/j.remn.2017.01.009. [PMID: 28257748] - Margret Schottelius, Theresa Osl, Andreas Poschenrieder, Frauke Hoffmann, Seval Beykan, Heribert Hänscheid, Andreas Schirbel, Andreas K Buck, Saskia Kropf, Markus Schwaiger, Ulrich Keller, Michael Lassmann, Hans-Jürgen Wester. [177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent.
Theranostics.
2017; 7(9):2350-2362. doi:
10.7150/thno.19119. [PMID: 28744319] - Sumanta K Pal, Neeraj Agarwal. Kidney cancer: Finding a niche for girentuximab in metastatic renal cell carcinoma.
Nature reviews. Urology.
2016 08; 13(8):442-3. doi:
10.1038/nrurol.2016.115. [PMID: 27349371] - Constantijn H J Muselaers, Marye J Boers-Sonderen, Tim J van Oostenbrugge, Otto C Boerman, Ingrid M E Desar, Alexander B Stillebroer, Sasja F Mulder, Carla M L van Herpen, Johan F Langenhuijsen, Egbert Oosterwijk, Wim J G Oyen, Peter F A Mulders. Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
European urology.
2016 05; 69(5):767-70. doi:
10.1016/j.eururo.2015.11.033. [PMID: 26706103]